Klas Gosta Wiman
Corporate Officer/Principal chez Karolinska Institutet
Profil
Klas Gosta Wiman is the founder of Aprea Therapeutics, Inc. (founded in 2002) and Aprea Therapeutics AB (founded in 2003).
He is currently working as a Professor in the Oncology & Pathology Department at Karolinska Institutet.
Postes actifs de Klas Gosta Wiman
| Sociétés | Poste | Début |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | 15/05/2009 |
Anciens postes connus de Klas Gosta Wiman
| Sociétés | Poste | Fin |
|---|---|---|
| APREA THERAPEUTICS, INC. | Fondateur | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APREA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
